Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drooling treatment shows promise in Year-Long study

NCT ID NCT02610868

First seen Apr 23, 2026 · Last updated May 24, 2026 · Updated 8 times

Summary

This study tested a medication called MYOBLOC for adults who have troublesome drooling (sialorrhea) due to conditions like Parkinson's disease, stroke, or ALS. Over one year, 187 participants received repeated injections to see if it safely reduces drooling. The main goal was to check for side effects and track how well the treatment works over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SIALORRHEA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Study site

    Phoenix, Arizona, 85013, United States

  • Study site

    Scottsdale, Arizona, 85258, United States

  • Study site

    Scottsdale, Arizona, 85259, United States

  • Study site

    Loma Linda, California, 92354, United States

  • Study site

    Los Angeles, California, 90033, United States

  • Study site

    Aurora, Colorado, 80045, United States

  • Study site

    Atlantis, Florida, 33462, United States

  • Study site

    Boca Raton, Florida, 33486, United States

  • Study site

    Orlando, Florida, 32806, United States

  • Study site

    Port Charlotte, Florida, 33980, United States

  • Study site

    Atlanta, Georgia, 30329, United States

  • Study site

    Kansas City, Kansas, 66160, United States

  • Study site

    Overland Park, Kansas, 66211, United States

  • Study site

    Elkridge, Maryland, 21075, United States

  • Study site

    Farmington Hills, Michigan, 48334, United States

  • Study site

    St Louis, Missouri, 63110, United States

  • Study site

    Las Vegas, Nevada, 89145, United States

  • Study site

    Edison, New Jersey, 08818, United States

  • Study site

    Centerville, Ohio, 45459, United States

  • Study site

    Tulsa, Oklahoma, 74136, United States

  • Study site

    Greenville, South Carolina, 29615, United States

  • Study site

    Cordova, Tennessee, 38018, United States

  • Study site

    San Antonio, Texas, 78229, United States

  • Study site

    Kirkland, Washington, 98034, United States

  • Study site

    Spokane, Washington, 99202, United States

  • Study site

    Tacoma, Washington, 98409, United States

  • Study site

    Grodno, 230017, Belarus

  • Study site

    Dnipropetrovsk, 49027, Ukraine

  • Study site

    Ivano-Frankivsk, 76008, Ukraine

  • Study site

    Kharkiv, 61068, Ukraine

  • Study site

    Lviv, 79010, Ukraine

  • Study site

    Odesa, 65025, Ukraine

  • Study site

    Rivne, 33010, Ukraine

  • Study site

    Uzhhorod, 88018, Ukraine

  • Study site

    Zaporizhzhya, 69600, Ukraine

Conditions

Explore the condition pages connected to this study.